NASDAQ:MRVI Maravai LifeSciences (MRVI) Stock Forecast, Price & News $13.33 +0.16 (+1.21%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$13.14▼$13.5750-Day Range$12.09▼$15.0052-Week Range$11.59▼$33.81Volume1.57 million shsAverage Volume4.78 million shsMarket Capitalization$3.35 billionP/E Ratio11.59Dividend YieldN/APrice Target$19.80 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Maravai LifeSciences MarketRank™ ForecastAnalyst RatingModerate Buy2.56 Rating ScoreUpside/Downside48.5% Upside$19.80 Price TargetShort InterestBearish6.71% of Float Sold ShortDividend StrengthN/ASustainability-1.23Upright™ Environmental ScoreNews Sentiment0.72Based on 10 Articles This WeekInsider TradingN/AProj. Earnings Growth33.33%From $0.30 to $0.40 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.71 out of 5 starsMedical Sector68th out of 983 stocksPharmaceutical Preparations Industry26th out of 486 stocks 3.3 Analyst's Opinion Consensus RatingMaravai LifeSciences has received a consensus rating of Buy. The company's average rating score is 2.56, and is based on 5 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.80, Maravai LifeSciences has a forecasted upside of 48.5% from its current price of $13.33.Amount of Analyst CoverageMaravai LifeSciences has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.71% of the float of Maravai LifeSciences has been sold short.Short Interest Ratio / Days to CoverMaravai LifeSciences has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Maravai LifeSciences has recently increased by 21.17%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMaravai LifeSciences does not currently pay a dividend.Dividend GrowthMaravai LifeSciences does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMaravai LifeSciences has received a 67.24% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Deoxyribonucleic acid (DNA)", "Microbiology laboratory services for research", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Maravai LifeSciences is -1.23. Previous Next 3.7 News and Social Media Coverage News SentimentMaravai LifeSciences has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Maravai LifeSciences this week, compared to 4 articles on an average week.Search Interest1 people have searched for MRVI on MarketBeat in the last 30 days. MarketBeat Follows5 people have added Maravai LifeSciences to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Maravai LifeSciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.11% of the stock of Maravai LifeSciences is held by insiders.Percentage Held by Institutions48.67% of the stock of Maravai LifeSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Maravai LifeSciences are expected to grow by 33.33% in the coming year, from $0.30 to $0.40 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Maravai LifeSciences is 11.59, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.95.Price to Earnings Ratio vs. SectorThe P/E ratio of Maravai LifeSciences is 11.59, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 120.17.Price to Book Value per Share RatioMaravai LifeSciences has a P/B Ratio of 3.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Maravai LifeSciences (NASDAQ:MRVI) StockMaravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.Read More Receive MRVI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Maravai LifeSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address MRVI Stock News HeadlinesJune 2, 2023 | americanbankingnews.comMaravai LifeSciences Sees Unusually High Options Volume (NASDAQ:MRVI)June 1, 2023 | americanbankingnews.comMaravai LifeSciences (NASDAQ:MRVI) Shares Down 6% June 4, 2023 | Behind the Markets (Ad)How A.I. Could Make Most 21st Century Diseases EXTINCTOn December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...May 31, 2023 | msn.comMaravai gains amid report of $17 a share takeover bid from Thomas H. LeeMay 30, 2023 | markets.businessinsider.comStifel Nicolaus Remains a Buy on Maravai Lifesciences Holdings (MRVI)May 25, 2023 | americanbankingnews.comMaravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Receives $20.67 Average Target Price from BrokeragesMay 24, 2023 | finance.yahoo.comTriLink BioTechnologies® Announces Manufacturing Capabilities Expansion as mRNA Manufacturing Facility Nears CompletionMay 23, 2023 | msn.comCredit Suisse Downgrades Maravai LifeSciences Holdings Inc - (MRVI)June 4, 2023 | Behind the Markets (Ad)How A.I. Could Make Most 21st Century Diseases EXTINCTOn December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...May 23, 2023 | americanbankingnews.comMaravai LifeSciences (NASDAQ:MRVI) Downgraded to "Neutral" at Credit Suisse GroupMay 19, 2023 | americanbankingnews.comMaravai LifeSciences Target of Unusually Large Options Trading (NASDAQ:MRVI)May 17, 2023 | americanbankingnews.comMaravai LifeSciences (NASDAQ:MRVI) Trading Down 2.7%May 17, 2023 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Maravai Lifesciences Holdings (MRVI)May 16, 2023 | reuters.comExclusive: Vaccine reagent vendor Maravai draws private equity interest-sourcesMay 16, 2023 | markets.businessinsider.comMaravai LifeSciences Shares Fall After Rejecting Potential Takeover By Private EquityMay 16, 2023 | markets.businessinsider.comRBC Capital Remains a Buy on Maravai Lifesciences Holdings (MRVI)May 15, 2023 | seekingalpha.comMaravai LifeSciences Holdings: Navigating The Covid CliffMay 12, 2023 | americanbankingnews.comMaravai LifeSciences (NASDAQ:MRVI) Downgraded by The Goldman Sachs Group to "Neutral"May 12, 2023 | msn.comMorgan Stanley Maintains Maravai LifeSciences Holdings Inc - (MRVI) Overweight RecommendationMay 12, 2023 | americanbankingnews.comFY2023 EPS Estimates for Maravai LifeSciences Holdings, Inc. Decreased by Analyst (NASDAQ:MRVI)May 11, 2023 | msn.comUnusual Call Option Trade in Maravai LifeSciences Holdings Inc - (MRVI) Worth $90.00KMay 11, 2023 | msn.comDeutsche Bank Maintains Maravai LifeSciences Holdings Inc - (MRVI) Buy RecommendationMay 11, 2023 | seekingalpha.comMaravai LifeSciences ticks higher amid renewed takeover speculationMay 11, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Cut by AnalystMay 11, 2023 | americanbankingnews.comMaravai LifeSciences (NASDAQ:MRVI) PT Lowered to $23.00May 11, 2023 | americanbankingnews.comMaravai LifeSciences (NASDAQ:MRVI) Price Target Cut to $18.00May 11, 2023 | msn.comRBC Capital Maintains Maravai LifeSciences Holdings Inc - (MRVI) Outperform RecommendationSee More Headlines MRVI Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MRVI Company Calendar Last Earnings5/08/2023Today6/03/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MRVI CUSIPN/A CIK1823239 Webwww.maravai.com Phone858-546-0004FaxN/AEmployees470Year FoundedN/APrice Target and Rating Average Stock Price Forecast$19.80 High Stock Price Forecast$29.00 Low Stock Price Forecast$14.00 Forecasted Upside/Downside+48.5%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$1.15 Trailing P/E Ratio11.59 Forward P/E Ratio44.43 P/E GrowthN/ANet Income$220.21 million Net Margins21.36% Pretax Margin52.96% Return on Equity38.41% Return on Assets14.57% Debt Debt-to-Equity Ratio0.60 Current Ratio6.13 Quick Ratio5.69 Sales & Book Value Annual Sales$883 million Price / Sales3.79 Cash Flow$1.98 per share Price / Cash Flow6.72 Book Value$3.59 per share Price / Book3.71Miscellaneous Outstanding Shares250,980,000Free Float250,707,000Market Cap$3.35 billion OptionableNot Optionable Beta-0.23 Key ExecutivesMr. Carl W. Hull (Age 64)Co-Founder and Exec. Chairman & Interim CEO Comp: $1.78MMr. Kevin M. Herde (Age 51)Exec. VP & CFO Comp: $841.6kMr. Kurt Oreshack (Age 42)Exec. VP, Gen. Counsel & Sec. Comp: $701.4kMs. Christine Dolan (Age 55)Chief Operating Officer of Biologics Safety Testing Comp: $844.67kMr. Brian Neel (Age 47)Chief Operating Officer of Nucleic Acid Production Comp: $797.38kDr. Peter Michael Leddy Ph.D. (Age 60)Exec. VP & Chief Admin. Officer Ms. Debra HartSr. Director of Investor RelationsMs. Doreen PippenVP of MarketingMr. William Martin IIIPres of Biologics Safety TestingMore ExecutivesKey CompetitorsPTC TherapeuticsNASDAQ:PTCTImmunoGenNASDAQ:IMGNAxsome TherapeuticsNASDAQ:AXSMZai LabNASDAQ:ZLABAmicus TherapeuticsNASDAQ:FOLDView All CompetitorsInstitutional OwnershipPrelude Capital Management LLCSold 1,500 shares on 6/1/2023Ownership: 0.004%Toroso Investments LLCBought 19,105 shares on 5/23/2023Ownership: 0.012%JPMorgan Chase & Co.Sold 20,555 shares on 5/18/2023Ownership: 1.524%New York State Common Retirement FundSold 35,696 shares on 5/18/2023Ownership: 0.049%Thrivent Financial for LutheransBought 2,011,683 shares on 5/17/2023Ownership: 3.209%View All Institutional Transactions MRVI Stock - Frequently Asked Questions Should I buy or sell Maravai LifeSciences stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Maravai LifeSciences in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MRVI shares. View MRVI analyst ratings or view top-rated stocks. What is Maravai LifeSciences' stock price forecast for 2023? 9 Wall Street analysts have issued 12 month target prices for Maravai LifeSciences' shares. Their MRVI share price forecasts range from $14.00 to $29.00. On average, they predict the company's share price to reach $19.80 in the next year. This suggests a possible upside of 48.5% from the stock's current price. View analysts price targets for MRVI or view top-rated stocks among Wall Street analysts. How have MRVI shares performed in 2023? Maravai LifeSciences' stock was trading at $14.31 on January 1st, 2023. Since then, MRVI shares have decreased by 6.8% and is now trading at $13.33. View the best growth stocks for 2023 here. Are investors shorting Maravai LifeSciences? Maravai LifeSciences saw a increase in short interest in May. As of May 15th, there was short interest totaling 7,270,000 shares, an increase of 21.2% from the April 30th total of 6,000,000 shares. Based on an average trading volume of 2,290,000 shares, the days-to-cover ratio is presently 3.2 days. Currently, 6.7% of the company's stock are short sold. View Maravai LifeSciences' Short Interest. When is Maravai LifeSciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our MRVI earnings forecast. How were Maravai LifeSciences' earnings last quarter? Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) released its quarterly earnings results on Monday, May, 8th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.04 by $0.01. The business had revenue of $79.03 million for the quarter, compared to analyst estimates of $79.72 million. Maravai LifeSciences had a net margin of 21.36% and a trailing twelve-month return on equity of 38.41%. The business's quarterly revenue was down 67.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.54 earnings per share. What ETFs hold Maravai LifeSciences' stock? ETFs with the largest weight of Maravai LifeSciences (NASDAQ:MRVI) stock in their portfolio include Direxion mRNA ETF (MSGR), Janus Henderson Small Cap Growth Alpha ETF (JSML), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), Putnam BioRevolution ETF (SYNB), Distillate Small/Mid Cash Flow ETF (DSMC), Renaissance IPO ETF (IPO), Pacer US Large Cap Cash Cows Growth Leaders ETF (COWG) and Vanguard U.S. Quality Factor ETF (VFQY). What guidance has Maravai LifeSciences issued on next quarter's earnings? Maravai LifeSciences updated its FY 2023 earnings guidance on Monday, May, 8th. The company provided earnings per share guidance of $0.27-$0.33 for the period, compared to the consensus EPS estimate of $0.35. The company issued revenue guidance of $400.00 million-$440.00 million, compared to the consensus revenue estimate of $430.17 million. When did Maravai LifeSciences IPO? (MRVI) raised $1.3 billion in an initial public offering on Friday, November 20th 2020. The company issued 50,000,000 shares at $24.00-$27.00 per share. Morgan Stanley, Jefferies and Goldman Sachs acted as the underwriters for the IPO and BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel, Keybanc Securities, Academy Securities, Loop Capital Markets, Penserra Securities and Tigress Financial Partners were co-managers. What is Maravai LifeSciences' stock symbol? Maravai LifeSciences trades on the NASDAQ under the ticker symbol "MRVI." Who are Maravai LifeSciences' major shareholders? Maravai LifeSciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Thrivent Financial for Lutherans (3.21%), BlackRock Inc. (2.31%), JPMorgan Chase & Co. (1.52%), Clearbridge Investments LLC (1.27%), Renaissance Technologies LLC (1.25%) and Mackenzie Financial Corp (0.99%). How do I buy shares of Maravai LifeSciences? Shares of MRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Maravai LifeSciences' stock price today? One share of MRVI stock can currently be purchased for approximately $13.33. How much money does Maravai LifeSciences make? Maravai LifeSciences (NASDAQ:MRVI) has a market capitalization of $3.35 billion and generates $883 million in revenue each year. The company earns $220.21 million in net income (profit) each year or $1.15 on an earnings per share basis. How many employees does Maravai LifeSciences have? The company employs 470 workers across the globe. How can I contact Maravai LifeSciences? Maravai LifeSciences' mailing address is 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.maravai.com. The company can be reached via phone at 858-546-0004 or via email at ir@maravai.com. This page (NASDAQ:MRVI) was last updated on 6/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maravai LifeSciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.